$ARIA ... this is positive news for "future" growth? RoyalHouseOfRock (@RoyalHouseOfRock) Jun. 2 at 10:00 AM
MannKind shares rose nearly 3% ahead of the company's presentation at the Jefferies 2014 Global Health Care Conference, scheduled for today at 2:30 p.m. Investors hoped to hear positive news about Afrezza, MannKind's inhaled insulin treatment for diabetics.
$MNKD 4 hours left to the beginning of the conference.? Donna Peran (@donnaperan) Jun. 2 at 10:20 AM
Afrezza is pending FDA-approval and was overwhelmingly recommended by an FDA subcommittee earlier this year, despite concerns about lung complications with the drug. Investors believe that the drug could take over the $45 billion diabetes-management market, as many diabetics would prefer a treatment that doesn't involve daily shots. Sentiment on the stock is 97% bullish, according to StockTwits analytics.
$MNKD added few more. Like the way she's holding. Expecting a strong action EOD? Saif Ross (@Rossx) Jun. 2 at 10:24 AM
NPS Pharmaceuticals shares were up nearly 15% by 11 a.m. after a report in the Financial Times that Shire (SHPG) is considering acquiring the company. And investors on StockTwits.com said shares should could climb higher than the $35.61 if rumors prove true that Shire secured a $5 billion credit facility to make a bid for the drug company, which focuses on treatments for people with rare disorders.
Pharmacyclics rose more than 2% after the company announced that its FDA-approved Imbruvica cancer drug boosted the survival rates of patients with leukemia or small lymphocytic lymphoma better than competing drugs. Patients who received the drug had a 78% reduction in the risk of cancer progression or death.
Sentiment on the stock was overwhelmingly bullish, with 89% of the crowd on StockTwits calling for gains, according to site analytics.
$PCYC This is a good stock to be in if you are not on a 1 - 2 day time horizon. Great data, FDA approved, sales ramping up.? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:40 AM
Risk is commercialization and potential competitors. That being said, Rx up and great data show Imbruvica can compete vs. Gild/Abbv.? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:43 AM
>>Read More: Delta Boosts Order for the Newly Stylish Airbus A321
>>Read More: Coal Shares React Positively to EPA Emissions Rules
At the time of publication, the author held no positions in any of the stocks mentioned.
This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.